4 research outputs found
Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC.
peer reviewedLate relapse (LR) after allogeneic hematopoietic stem cell transplantation (AHSCT) for acute leukemia is a rare event (nearly 4.5%) and raises the questions of prognosis and outcome after salvage therapy. We performed a retrospective multicentric study between January 1, 2010, and December 31, 2016, using data from the French national retrospective register ProMISe provided by the SFGM-TC (French Society for Bone Marrow Transplantation and Cellular Therapy). We included patients presenting with LR, defined as a relapse occurring at least 2 years after AHSCT. We used the Cox model to identify prognosis factors associated with LR. During the study period, a total of 7582 AHSCTs were performed in 29 centers, and 33.8% of patients relapsed. Among them, 319 (12.4%) were considered to have LR, representing an incidence of 4.2% for the entire cohort. The full dataset was available for 290 patients, including 250 (86.2%) with acute myeloid leukemia and 40 (13.8%) with acute lymphoid leukemia. The median interval from AHSCT to LR was 38.2 months (interquartile range [IQR], 29.2 to 49.7 months), and 27.2% of the patients had extramedullary involvement at LR (17.2% exclusively and 10% associated with medullary involvement). One-third of the patients had persistent full donor chimerism at LR. Median overall survival (OS) after LR was 19.9 months (IQR, 5.6 to 46.4 months). The most common salvage therapy was induction regimen (55.5%), with complete remission (CR) obtained in 50.7% of cases. Ninety-four patients (38.5%) underwent a second AHSCT, with a median OS of 20.4 months (IQR, 7.1 to 49.1 months). Nonrelapse mortality after second AHSCT was 18.2%. The Cox model identified the following factors as associated with delay of LR: disease status not in first CR at first HSCT (odds ratio [OR], 1.31; 95% confidence interval [CI], 1.04 to 1.64; PÂ =Â .02) and the use of post-transplantation cyclophosphamide (OR, 2.23; 95% CI, 1.21 to 4.14; PÂ =Â .01). Chronic GVHD appeared to be a protective factor (OR, .64; 95% CI, .42 to .96; PÂ =Â .04). The prognosis of LR is better than in early relapse, with a median OS after LR of 19.9 months. Salvage therapy associated with a second AHSCT improves outcome and is feasible, without creating excess toxicity
The Socio-Ecological Adaptation of Released Chimpanzees in Guinea, West Africa
Throughout their range across Africa, chimpanzees (Pan troglodytes) are threatened with
extinction due to habitat destruction, disease and unsustainable levels of hunting and capture, in spite of being protected by national and international laws. In recent years, the bush meat and the pet trade have resulted in a significant increase in the number confiscated orphan chimpanzees. The Chimpanzee Conservation Centre (CCC), located in the High Niger National Park (HNNP), is the only Pan African Sanctuary Alliance (PASA)-accredited sanctuary caring for chimpanzee orphans in Guinea, West Africa. This sanctuary has been rehabilitating confiscated chimpanzees since 1997. With the aim of reinforcing the wild chimpanzee population of the HNNP and to enhance park protection, the CCC, in 2008, released a first group of 12 chimpanzees into the Mafou core area of the park. Five of those individuals have since settled at the release site and continue to be monitored. In August 2011, the CCC was able to re-enforce this resident group with the successful addition of 2 adult females. Post-release monitoring of these individuals involved distance monitoring using simple VHF and/or ARGOS and GPS store-on-board radio collars. Here, we present data downloaded in 2011–2012 from the GPS store-on-board collars of 2 adult males and these 2 additional adult females. These data allowed us to analyse their social dynamics, party composition, habitat preferences, day range and home range use. Our results indicate that these females integrated successfully into the resident group and that the behaviour of these wild-born released orphan chimpanzees mirrors that of wild counterparts inhabiting similar savannah dominated landscapes, suggesting that they have adapted appropriately to their release conditions
Building a haemophilia-specific navigator in Epic® Electronic Health Records: Single-centre preliminary experience
Reevaluation of ATR signaling in primary resting chronic lymphocytic leukemia cells: evidence for pro-survival or pro-apoptotic function
ATM, primarily activated by DNA double-strand breaks, and ATR, activated by single-stranded DNA, are master regulators of the cellular response to DNA damage. In primary chronic lymphocytic leukemia (CLL) cells, ATR signaling is considered to be switched off due to ATR downregulation. Here, we hypothesized that ATR, though expressed at low protein level, could play a role in primary resting CLL cells after genotoxic stress. By investigating the response of CLL cells to UV-C irradiation, a prototypical activator of ATR, we could detect phosphorylation of ATR at Thr-1989, a marker for ATR activation, and also observed that selective ATR inhibitors markedly decreased UV-C-induced phosphorylation of ATR targets, including H2AX and p53. Similar results were obtained with the purine analogs fludarabine and cladribine that were also shown to activate ATR and induce ATR-dependent phosphorylation of H2AX and p53. In addition, ATR inhibition was found to sensitize primary CLL cells to UV-C by decreasing DNA repair synthesis. Conversely, ATR inhibition rescued CLL cells against purine analogs by reducing expression of the pro-apoptotic genes PUMA and BAX. Collectively, our study indicates that ATR signaling can be activated in resting CLL cells and play a pro-survival or pro-apoptotic role, depending on the genotoxic context